| Full Name | Eric Lewis |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 30 Years |
| Location | 400 E 1st St, Morris, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467465518 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 40053 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Stevens Community Medical Center | Morris, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Stevens Community Medical Center Inc | 3678475852 | 52 |
News Archive
A new study shows that the initially lauded combination of drugs against COVID-19 - Hydroxychloroquine and Chloroquine combined with azithromycin, could lead to abnormal and life-threatening heart rhythms. In patients hospitalized with the novel coronavirus infection or SARS CoV-2, this combination can lead to prolonged QT interval as can be detected on ECG.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma's FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.
New proposals by Britain's Labour government will see children banned from starting primary school unless they have been vaccinated.
The risk of miscarriage is 2.4 times greater for women who took any type and dosage of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) in early pregnancy, according to a University of Montreal study in CMAJ.
› Verified 8 days ago
| Entity Name | Stevens Community Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417105552 PECOS PAC ID: 3678475852 Enrollment ID: O20040127000493 |
News Archive
A new study shows that the initially lauded combination of drugs against COVID-19 - Hydroxychloroquine and Chloroquine combined with azithromycin, could lead to abnormal and life-threatening heart rhythms. In patients hospitalized with the novel coronavirus infection or SARS CoV-2, this combination can lead to prolonged QT interval as can be detected on ECG.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma's FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.
New proposals by Britain's Labour government will see children banned from starting primary school unless they have been vaccinated.
The risk of miscarriage is 2.4 times greater for women who took any type and dosage of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) in early pregnancy, according to a University of Montreal study in CMAJ.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Eric Lewis, MD 400 E 1st St, Morris, MN 56267-0660 Ph: (320) 589-1313 | Eric Lewis, MD 400 E 1st St, Morris, MN 56267-0660 Ph: (320) 589-1313 |
News Archive
A new study shows that the initially lauded combination of drugs against COVID-19 - Hydroxychloroquine and Chloroquine combined with azithromycin, could lead to abnormal and life-threatening heart rhythms. In patients hospitalized with the novel coronavirus infection or SARS CoV-2, this combination can lead to prolonged QT interval as can be detected on ECG.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma's FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.
New proposals by Britain's Labour government will see children banned from starting primary school unless they have been vaccinated.
The risk of miscarriage is 2.4 times greater for women who took any type and dosage of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) in early pregnancy, according to a University of Montreal study in CMAJ.
› Verified 8 days ago